US Market

Global Pharma Healthcare is recalling 50,000 tubes of eye drops in the US market due to bacterial contamination, according to the US Food and Drug Administration (USFDA). As per its latest Enforcement Report, the US health regulator noted that the Chennai-based drug firm is recalling the affected lot of eye lubricant for artificial tears which have been linked to vision loss in the US. The lot has been manufactured by Chennai-based Global Pharma Healthcare and distributed in the US market by New York-based Delsam Pharma, the USFDA said. Stating the reason for recall, the US health regulator said: "FDA analysis found unopened tubes to be contaminated with bacteria." The company initiated the Class I recall on February 24 this year. As per the USFDA, a Class I recall is the most urgent of the three types of FDA recalls and usually pertains to defective products that can cause serious health problems. In February, Global Pharma Healthcare had announced that it is recalling its entir

New launches in the US, market share gains and steady domestic growth are positives

Silicon Valley Bank crisis: How has the bank's failure affected other banks and their stocks worldwide? Read more to find out

Steady outlook and higher returns triggers for companies refining their strategy

HealthKart operates two verticals in the Indian market, MuscleBlaze, a sports nutrition brand, and HKVitals, an online health supplement brand

During the week, the Sensex fell 2.4 per cent and the Nifty 2.5 per cent, their worst weekly decline since June 17, 2022

The stock has underperformed peers and the benchmark over the past year

Harappa founders cite huge scope as 82% Americans are likely to quit their jobs because of a bad manager, while 44% managers feel they are unprepared for their jobs

According to Statista, audio OTT market in India is expected to be worth $2.5 billion by 2030

With the benefit of hindsight, India's stealth bull market is underpinned by some strong positives. The most important of these is earnings growth across different sectors

Gross sales came in at Rs 10,809.2 crore, growing by 13.1% over Q2 last year

Profit was up sequentially, however; Revenue rose 20.7% YoY and 3.3% QoQ, driven by growth in CME segment and the US market

Excluding the strong US show led by Revlimid, Q2 was a mixed bag

While domestic market demand is strong, analysts expect higher raw material and freight costs to affect business in US, other countries; healthy YoY growth seen in hospitals and diagnostics

The UK's credit outlook was lowered to negative from stable by Fitch Ratings, which cited risk the government's new growth plan could increase the nation's fiscal deficit

Investors bracing for another jumbo Federal Reserve rate hike are focused on a few key trades: betting on deeper inversion in the US yield curve, further losses in stocks and a stronger dollar

On Friday, Fed chair Jerome Powell signaled the US central bank is likely to keep hiking interest rates and keep them elevated to tame inflation.

CLOSING BELL: Tata Steel fell over 4 per cent, while Asian Paints, Wipro, L&T, Bajaj twins, Ultratech Cement, Axis Bank, Sun Pharma, Tech M, ICICI Bank, & SBI declined in the range of 2-3.5 per cent

Drug firm Wockhardt on Saturday said it has tied up with various partners to roll out products in the US market with its Illinois-based manufacturing plant all set to relieve all workers in a phased manner as part of business restructuring in the US market. The Mumbai-based company said it has engaged multiple US Food and Drug Administration (USFDA) approved manufacturing partners in the US market, after thorough due diligence and inspection of their facilities, to manufacture various products for sale in the US/ North America. "The company is relieving all its staff who were directly engaged by our US subsidiary in its plant in connection with the manufacturing process in a phased manner and in full compliance with the applicable local laws," Wockhardt Ltd said in a regulatory filing. This new arrangement is in the best interest of the company as it will help avoid the manufacturing and quality management cost completely resulting in significant savings in operating and overhead co

Berkshire has spent this year wagering more on Occidental after first making a bet on the Houston-based oil company three years ago